New light-based cancer treatment combined with immunotherapy for recurring head and neck cancer

Plain-English translation of NCT06699212 on ClinicalTrials.gov ↗ · Source last updated October 2025 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a new treatment called ASP-1929 photoimmunotherapy—a medication that is activated by red light—combined with , a drug that helps your immune system fight cancer. The trial is comparing this new combination against standard cancer treatments to see if it works better for people whose head and neck cancer has returned locally without spreading to distant parts of the body.

Patients with recurring head and neck cancer need better treatment options with fewer side effects. This medication uses a novel approach by combining a light-activated drug with an immune-boosting treatment to target cancer cells more directly while activating the body's natural defenses.

Do you qualify?

You likely qualify if…

you have been diagnosed with squamous cell carcinoma (a type of head and neck cancer) that has come back in the same area but has not spread to distant parts of your body
your cancer has at least one tumor that is visible and can be reached with light treatment
you have never been treated with anti-PD-1 or anti-PD-L1 immunotherapy drugs before
you have a good performance status (you are able to care for yourself with minimal or no assistance from others)
you have adequate organ function (healthy kidneys, liver, and blood counts) as shown by blood tests
if you are a woman of childbearing potential, you are willing to use effective birth control during and after the study

You likely don't qualify if…

you have been diagnosed with or treated for another cancer within the past 2 years (except for non-serious skin cancers or cancers with very low risk)
you have had a severe allergic reaction to a similar cancer drug (cetuximab) before
you have an active autoimmune disease that required treatment with steroids or immune-suppressing drugs in the past 2 years
you have active lung inflammation, tuberculosis, hepatitis B or C, HIV, or other serious active infections
you have cancer that has spread to your brain or the protective lining around your brain

What participation looks like

If you join this study, you will receive either the new light-activated medication combined with or standard treatment, depending on which group you are randomly assigned to. The new treatment involves an infusion of the medication followed by exposure to red light at the tumor site, repeated every 4 to 6 weeks, along with regular infusions of (typically every 3 weeks at first). You will be treated for up to 24 months and will have regular visits to the hospital or clinic for treatment infusions, blood tests, and scans to monitor how well the treatment is working.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

New light-based cancer treatment combined with immunotherapy for recurring head and neck cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(22 sites)